These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32839900)

  • 61. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
    Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
    Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer.
    Kim JY; Park HS; Kim S; Ryu J; Park S; Kim SI
    Medicine (Baltimore); 2015 Oct; 94(43):e1720. PubMed ID: 26512562
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Discordant Breast and Axillary Pathologic Response to Neoadjuvant Chemotherapy.
    Flores R; Roldan E; Pardo JA; Beight L; Ubellacker J; Fan B; Davis RB; James TA
    Ann Surg Oncol; 2023 Dec; 30(13):8302-8307. PubMed ID: 37606840
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype.
    Al-Hilli Z; Hoskin TL; Day CN; Habermann EB; Boughey JC
    Ann Surg Oncol; 2018 Feb; 25(2):482-493. PubMed ID: 29181679
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer.
    Grova MM; Strassle PD; Navajas EE; Gallagher KK; Ollila DW; Downs-Canner SM; Spanheimer PM
    Ann Surg Oncol; 2021 Apr; 28(4):2182-2190. PubMed ID: 32974693
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit.
    Spronk PER; Volders JH; van den Tol P; Smorenburg CH; Vrancken Peeters MTFD
    Eur J Surg Oncol; 2019 Feb; 45(2):110-117. PubMed ID: 30348601
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A prospective cohort study identifying radiologic and tumor related factors of importance for breast conserving surgery after neoadjuvant chemotherapy.
    Gulis K; Ellbrant J; Svensjö T; Skarping I; Vallon-Christersson J; Loman N; Bendahl PO; Rydén L
    Eur J Surg Oncol; 2023 Jul; 49(7):1189-1195. PubMed ID: 37019807
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Does neoadjuvant chemotherapy provide any benefit for surgical de-escalation in luminal B, HER2(-) breast cancers?
    Aktas A; Gunay-Gurleyik M; Aker F; Kaan-Akgok Y; Atag E
    Cir Cir; 2023; 91(2):186-194. PubMed ID: 37084295
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?
    van de Loo ME; Andour L; van Heesewijk AE; Oosterkamp HM; Liefers GJ; Straver ME
    Breast Cancer Res Treat; 2024 May; 205(1):5-16. PubMed ID: 38265568
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Neo-Adjuvant chemotherapy and its affects to the axilla-Can we safely downgrade axillary surgery to mirror the approach in the breast.
    Batt J; Chambers A; Al-Allak A; Vestey S; Hunt R; Massey E; Fowler C
    Breast J; 2020 Sep; 26(9):1667-1672. PubMed ID: 32767467
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neoadjuvant chemotherapy for stage II-III breast cancer: a single-center experience.
    Zaher HAE; Fathy H; Abozeid M; Faisal M
    World J Surg Oncol; 2023 Oct; 21(1):314. PubMed ID: 37805553
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
    Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
    J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery.
    Kozak MM; Horst KC; Gutkin PM; Jacobson CE; Walck E; von Eyben R; Dirbas FM
    Clin Breast Cancer; 2020 Oct; 20(5):431-438. PubMed ID: 32522481
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of Breast Cancer Pretreatment Nodal Burden and Disease Subtype on Axillary Surgical Management.
    Ng S; Sabel MS; Hughes TM; Chang AE; Dossett LA; Jeruss JS
    J Surg Res; 2021 May; 261():67-73. PubMed ID: 33421795
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.
    Weber JJ; Jochelson MS; Eaton A; Zabor EC; Barrio AV; Gemignani ML; Pilewskie M; Van Zee KJ; Morrow M; El-Tamer M
    J Am Coll Surg; 2017 Dec; 225(6):740-746. PubMed ID: 28919579
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Margin Assessment and Re-excision Rates for Patients Who Have Neoadjuvant Chemotherapy and Breast-Conserving Surgery.
    Cen C; Chun J; Kaplowitz E; Axelrod D; Shapiro R; Guth A; Schnabel F
    Ann Surg Oncol; 2021 Sep; 28(9):5142-5148. PubMed ID: 33635409
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer.
    Moldoveanu D; Hoskin TL; Day CN; Schulze AK; Goetz MP; Boughey JC
    Breast Cancer Res Treat; 2024 Feb; 203(3):419-428. PubMed ID: 37878154
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.
    Blumencranz P; Habibi M; Shivers S; Acs G; Blumencranz LE; Yoder EB; van der Baan B; Menicucci AR; Dauer P; Audeh W; Cox CE
    Ann Surg Oncol; 2023 Dec; 30(13):8353-8361. PubMed ID: 37658272
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nodal Response and Survival After Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer: 20-Year Experience from a Single Institution.
    An SJ; Thai CHNC; Ismail S; Agala CB; Hoang V; Feeney T; Lillie M; Wheless A; Selfridge JM; Ollila DW; Gallagher KK; Carey LA; Spanheimer PM
    Ann Surg Oncol; 2024 Dec; 31(13):8786-8794. PubMed ID: 39154153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.